The Feinstein Institutes for Medical Research announced that the U.S. Food and Drug Administration (FDA) has approved an imaging compound its researchers developed as a diagnostic tool for people with suspected parkinsonian syndromes, including Parkinson’s disease. Fluorodopa F18 (FDOPA) is an injectable compound used during a PET…
News
Parkinson’s News Today keeps you up-to-date with research into Parkinson’s disease as it emerges. We brought you daily coverage of experiments into the basic biology of Parkinson’s, results of clinical and pre-clinical trials, and key findings from Parkinson’s research around the globe. We look forward to bringing more such…
A Phase 1 clinical trial of MODAG Neuroscience Solutions’ lead candidate anle138b is now underway and recruiting healthy participants at its one site in Nottingham, England, to study the compound’s safety. The small molecule is being developed to treat multiple system atrophy (MSA), but holds the potential to…
Tasigna (nilotinib), an approved leukemia medication being tested as a repurposed treatment for Parkinson’s disease, was found to be safe and increased the levels of dopamine in the brain of patients with Parkinson’s disease, a Phase 2 trial shows. The findings were reported in a study, “Nilotinib…
Gosuranemab failed to meet its primary and key secondary goals in a Phase 2 study evaluating its use in treating progressive supranuclear palsy, an atypical parkinsonian disorder, its developer, Biogen, has announced. Based on these results, Biogen will cease the clinical development of gosuranemab for this and other neurodegenerative diseases…
Immunotherapy Reduced Alpha-synuclein Clumps, Improved Dopamine Levels in Parkinson’s Mouse Model
Antibodies that selectively target the misfolded form of the alpha-synuclein protein — that which underlies the development of Parkinson’s disease — reduced the formation of alpha-synuclein clumps and improved dopamine levels in a mouse model. The study with that finding also provided a framework for screening…
A new method allows researchers to develop adeno-associated virus (AVV) — commonly used as the vehicle for gene therapies — that accurately target and deliver genes to specific cells in the body. This new technology may be suitable to target dopaminergic neurons that are damaged in Parkinson’s disease. “We…
Sprint running is a safe and feasible form of physical exercise for people with mild-to-moderate Parkinson’s disease. That is the conclusion reached in the study, “Sprint exercise for subjects with mild-to-moderate Parkinson’s disease: Feasibility and biomechanical outputs,” was published in Clinical Biomechanics. Physical exercise has been…
In Parkinson’s patients, the risk of falls increases depending on disease duration and having the postural instability/gait disturbance (PIDG) subtype, but is not signficantly correlated with non-motor symptoms, a study suggests. The study, titled “Falls in persons with Parkinson’s disease: Do non-motor symptoms matter as much…
Interactive sessions, including games that are intended to help elderly Parkinson’s patients learn strategies to avoid falling, are well-received, a small Brazilian study suggests. The study, “Gerontotechnology for fall prevention of the elderly with Parkinson,” was published recently in Revista Brasileira de Enfermagem. Falling is a major…
Recent Posts
- When I became the unofficial offensive line in Parkinson’s quiet game
- The GPS of Theseus: Training the body’s navigation system with Parkinson’s
- New study highlights UTI risks in hospitalized Parkinson’s patients
- New exercise tips aim to help people with Parkinson’s stay active
- Getting approved for DBS surgery had me ‘feelin’ good as hell’